TG Therapeutics Inc Equity-NMS: TGTX

$- -39.34 (January 1, 1970)

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.
Powered by Vested Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly
Loading, Please wait...
Previous close :$39.34
Open :$37.94
Today's high :$38.83
Today's low :$37.67
52W low :$12.93
52W high :$43.32
EPS(TTM): :0.15
Shares O/S :157.07 M
Market cap :6.06 B

Compare with Other Stocks

Stocks Price 1D PE Market Cap
TG Therapeutics Inc $- -0.38% 262.27 6.06B

Frequently Asked Questions

What is the share price of TG Therapeutics Inc today?

TG Therapeutics Inc (TGTX) share price as of January 1, 1970, is $. If you are investing from India, you can always check the valuation in the INR before investing.

About TG Therapeutics Inc

TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.